| Literature DB >> 25126532 |
Viveksarathi Kunasekaran1, Kannan Krishnamoorthy1.
Abstract
The objective of this study was to select best method for the development of rasagiline mesylate (RM) loaded nanoscale solid lipid particles using analytic hierarchy process (AHP). Improper method selection may lead to waste of time, loss of material and financial resources. One of the possibilities to overcome these difficulties, AHP was employed to find the suitable method. In the AHP, a decision of hierarchy was constructed with a goal, criteria, sub-criteria, and alternatives. After constructing the AHP, the expert choice software was used to compute the overall priority of criteria, sub-criteria and alternatives. The best alternative selected was based on the highest priority. Nanoscale solid lipid particles of RM was formulated by the selected microemulsion method (M4) and it shows the particle size, polydispersity index and zeta potential were within acceptable limits. Drug content and entrapment efficiency of the RM-solid lipid nanoparticles were 97.26% and 86.57%, respectively. This study concludes that the AHP was viable and effective tool for selecting a most suitable method for the fabrication of RM loaded nanoscale solid lipid particles.Entities:
Keywords: Criteria; desirability; dynamic sensitivity analysis; hierarchy
Year: 2014 PMID: 25126532 PMCID: PMC4131401 DOI: 10.4103/2231-4040.137410
Source DB: PubMed Journal: J Adv Pharm Technol Res ISSN: 0976-2094
Saaty's pair-wise comparison nine point scale for AHP preference
Alternatives for the fabrication of drug loaded nanoscale solid lipid particles
Figure 1Four level hierarchy model for selection of best method for fabrication of rasagiline mesylate loaded solid lipid nanoparticles
Figure 2Dynamic sensitivity analysis graph
The composite priority weight for criteria, sub-criteria and alternatives
Figure 3Overall priority weights and ranking of sub-criteria
Figure 4Performance sensitivity graph
Characterization of fabricated RM-loaded SLN
Figure 5Particle size distribution of rasagiline mesylate solid lipid nanoparticles
Figure 6Zeta potential distribution of rasagiline mesylate solid lipid nanoparticles